CureVac Completes BioNTech-Driven Reorganization and Moves to Delist from Nasdaq
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CureVac ( (CVAC) ) just unveiled an update.
On January 6, 2026, CureVac N.V. completed a post-offer reorganization tied to BioNTech SE’s exchange offer, resulting in BioNTech becoming the sole owner of all CureVac business operations, with CureVac Merger B.V. succeeding CureVac via merger and eliminating all public shareholdings. The company notified Nasdaq on the same day, requested suspension of trading in its shares and the filing of a delisting notice, with the Nasdaq delisting expected to take effect on January 16, 2026, after which CureVac Merger plans to terminate the registration of CureVac shares with the U.S. Securities and Exchange Commission, effectively ending CureVac’s public reporting obligations and marking its transition from a publicly traded entity to a privately held BioNTech subsidiary, impacting shareholders by removing public market liquidity and signaling further consolidation in the mRNA biotech space.
The most recent analyst rating on (CVAC) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac’s strong financial performance and attractive valuation are the primary drivers of its overall score. The company’s robust profitability metrics and low leverage enhance its financial stability. However, technical analysis indicates some short-term bearish momentum, which slightly offsets the positive financial and valuation aspects.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac N.V. is a Germany-based biopharmaceutical company focused on the development of messenger RNA (mRNA)-based medicines, including vaccines and therapeutics, with its shares previously listed on the Nasdaq Global Market and targeting global healthcare and biotech investors.
Average Trading Volume: 1,132,067
Technical Sentiment Signal: Sell
Current Market Cap: $1.05B
Find detailed analytics on CVAC stock on TipRanks’ Stock Analysis page.
